Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04341246 · ClinicalTrials.gov registry record
Characterization and Technical Evaluation of cT1 for NASH (CATE-NASH)
A clinical trial, sponsored by Perspectum.
- Completed
- Registry status
- 28
- Enrollment target
NCT04341246: Completed study, sponsored by Perspectum.
NCT04341246 is a clinical trial that has completed, run by Perspectum. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04341246 has completed, sponsored by Perspectum.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate to provide evidence to establish tightly defined cut-offs to identify patients for NASH clinical trial inclusion using cT1 and/or PDFF. The study will be divided into 2 sub groups comprising of cases and controls.
Primary Outcome
Mean cT1 (and PDFF) values for those with NAS≥4\&F2-3 (cases) and those with NAS\<4 or F\<2 (controls)
Interventions
- DEVICE LiverMultiscan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-01-28 |
| Est. Completion | 2023-06-12 |
What the finished NCT04341246 record still lists
NCT04341246 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which LiverMultiscan is the first listed.
NCT04341246 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04341246 about?
NCT04341246 is a clinical study titled "Characterization and Technical Evaluation of cT1 for NASH (CATE-NASH)". The primary objective of this study is to evaluate to provide evidence to establish tightly defined cut-offs to identify patients for NASH clinical trial inclusion using cT1 and/or PDFF. The study will be divided into 2 sub groups comprising of cases and controls.
What is the current status of trial NCT04341246?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2021-01-28. Estimated completion is 2023-06-12.
What interventions are being tested in trial NCT04341246?
The interventions under investigation include: LiverMultiscan (DEVICE).
Who is sponsoring clinical trial NCT04341246?
This trial is sponsored by Perspectum, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI